Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2: solid-tumor therapy

M H Oppenheim1, M T Lotze

  • 1Section of Surgical Oncology, University of Pittsburgh Medical Center, Pa.

Oncology
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.

Cell death and differentiation·2025
Same author

Correction: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells.

Oncogene·2025
Same author

A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside.

HNO·2020
Same author

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer.

Cancer gene therapy·2015
Same journal

Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar.

Oncology·2026
Same journal

SF3A3 in Liver Hepatocellular Carcinoma: Oncogenic Role and Prognostic Significance.

Oncology·2026
Same journal

Letter to the Editor.

Oncology·2026
Same journal

FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Oncology·2026
Same journal

Longitudinal Changes in Body Weight and Body Mass Index in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Observational Study.

Oncology·2026
Same journal

Rising lung cancer burden attributable to high fasting plasma glucose in women aged ≥50 years: age-, SDI-, and BRICS-specific patterns from GBD 1990-2021.

Oncology·2026
See all related articles

Interleukin-2 (IL-2) demonstrates antitumor efficacy in human trials, inducing tumor regression alone or with other therapies. Further research into IL-2

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Interleukin-2 (IL-2) is a T cell-derived cytokine crucial for immune cell growth and activity.
  • IL-2 has demonstrated antitumor efficacy in human clinical trials, inducing tumor regression.
  • While initially used with lymphokine-activated killer cells, IL-2 alone is also effective.

Purpose of the Study:

  • To review the antitumor efficacy of Interleukin-2 (IL-2).
  • To examine the efficacy of IL-2 in combination with other therapies.
  • To explore the mechanisms and management of IL-2 toxicities.

Main Methods:

  • Review of human clinical trial data for IL-2 efficacy.
  • Analysis of combination therapy outcomes involving IL-2.
  • Investigation of potential mediators of IL-2 toxicity.

Related Experiment Videos

Main Results:

  • IL-2 alone induces tumor regression, comparable to combination therapies.
  • Combinations of IL-2 with chemotherapy or other cytokines have yielded disappointing results, except for interferon-alpha.
  • IL-2 toxicities are common, dose-limiting, and may involve mediators like TNF, IFN-gamma, and nitric oxide.

Conclusions:

  • Interleukin-2 is an effective immunotherapy agent for cancer treatment.
  • Understanding IL-2's antitumor mechanisms and toxicities is key to improving cancer therapies.
  • Further clinical studies are needed to optimize IL-2 treatment strategies and manage side effects.